Abstract | PURPOSE: METHODS AND MATERIALS: Between 1989 and 2005, a total of 20 patients with ACC of the trachea were treated with fast neutron radiotherapy at the University of Washington. Of these 20 patients, 19 were treated with curative intent. Neutron doses ranged from 10.7 to 19.95 Gy (median, 19.2 Gy). Six of these patients received an endobronchial brachytherapy boost using an HDR (192)Ir source (3.5 Gy x 2 fractions). Median duration of follow-up was 46 months (range, 10-121 months). RESULTS: The 5-year actuarial overall survival rate and median overall survival for the entire cohort were 89.4%, and 97 months, respectively. Overall survival was not statistically different among those patients receiving an endobronchial boost compared with those receiving neutron radiotherapy alone (100% vs. 68%, p = 0.36). The 5-year actuarial locoregional control rate for the entire cohort was 54.1%. The locoregional control rate was not statistically different among patients who received an endobronchial boost compared with those who received neutron radiotherapy alone (40% vs. 58%, p = 0.94). There were no cases of Grade > or =3 acute toxicity. There were 2 cases of Grade 3/4 chronic toxicity. CONCLUSIONS:
|
Authors | Nathan Bittner, Wui-Jin Koh, George E Laramore, Shilpen Patel, Michael S Mulligan, James G Douglas |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 72
Issue 2
Pg. 410-4
(Oct 01 2008)
ISSN: 0360-3016 [Print] United States |
PMID | 18374509
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Brachytherapy
(methods)
- Carcinoma, Adenoid Cystic
(mortality, pathology, radiotherapy, secondary)
- Female
- Humans
- Iridium Radioisotopes
(therapeutic use)
- Male
- Middle Aged
- Neutrons
(therapeutic use)
- Radiotherapy Dosage
- Salvage Therapy
- Survival Analysis
- Tracheal Neoplasms
(mortality, pathology, radiotherapy)
- Treatment Failure
|